New study tests Crohn's drug safety in kids
NCT ID NCT07564505
First seen May 08, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study looks at the safety and effectiveness of adalimumab, a drug used to control Crohn's disease, in 30 Chinese children aged 6 to 17 with moderate-to-severe active disease. Researchers will track side effects and how many children achieve remission over 12, 26, and 52 weeks. The goal is to better understand real-world use in this age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN AGED 6 YEARS AND ABOVE WITH MODERATE - TO - SEVERE ACTIVE CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.